A limb-girdle muscular dystrophy gene therapy Sarepta licensed last year faces its first clinical test.
Solid Biosciences should soon find out if its DMD gene therapy, SGT-001, could compete with Sarepta’s.
Digging into the sales forecasts for gene therapies shows just how low their penetration is expected to be. Could biopharma come to regret its high-price, low-volume…
Novo Nordisk is determined to dominate obesity, but two discontinuations hint that the ride might be rocky.
It could be hard for Macrogenics to shake off new safety concerns, whether it is the DART bispecific construct or its protein target that is to blame.
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
The first day of the haematology conference sees first-in-human data from two antibody-drug conjugates belonging to Immunogen, a company eager to draw a line under a…
The private UK group could steal the thunder of rivals like Spark, Uniqure and Biomarin.
The amyloid beta hypothesis persists in spite of repeated failure as biopharma refines targets and mechanisms of action.